APR 03, 2020 7:31 AM PDT

Trial Drug Successfully Blocks COVID-19 from Entering Cells

WRITTEN BY: Annie Lennon

An international team led by Canadian University of British Columbia researcher Dr. Josef Penninger has seen promising results from a trial drug capable of blocking the cellular doors typically exploited by COVID-19 to infect multiple human organs. 

In earlier work, Penninger and colleagues form the University of Vienna and the University of Toronto identified ACE2, an enzyme that attaches to the outer surfaces of cells in the lungs, arteries, heart, kidney and intestines, as a key receptor for SARS, considered as a global viral respiratory threat back in 2003. As the previous form of SARS is closely related to the present COVID-19 (SARS-CoV-2), the researchers suspected that a similar mechanism may be at play for COVID-19 too. 

To test this, they infected engineered replicas of human blood vessels and kidneys, organoids grown from human stem cells, with COVID-19. Seeing that the virus was able to directly affect and duplicate itself in these tissues, they then used a drug, known as APN01 (human recombinant soluble angiotensin-converting enzyme 2- hrsACE2) to tackle its spread. Ultimately, the researchers found that the drug managed to inhibit the COVID-19’s viral load in these tissues by a factor of 1,000- 5,000. 

Showing both how the virus may lead to multiple organ failure and how a potential new treatment option may work, Nuria Monserrat, one of the study’s authors said, “Using organoids allows us to test in a very agile way treatments that are already being used for other diseases, or that are close to being validated. In these moments in which time is short, human organoids save the time that we would spend to test a new drug in the human setting.”

Soon to enter clinical trials by the European biotechnology firm Apeiron Biologics, Penninger said, “Our previous work has helped to rapidly identify ACE2 as the entry gate for SARS-CoV-2, which explains a lot about the disease. Now we know that a soluble form of ACE2 that catches the virus away, could be indeed a very rational therapy that specifically targets the gate the virus must take to infect us. There is hope for this horrible pandemic."

 

Sources: Science Daily, News Hub

 

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
MAY 09, 2020
Chemistry & Physics
MAY 09, 2020
Blood test monitors fat intake
Research published in the Journal of Lipid Research highlights a new blood test that is able to monitor an individual&rs ...
MAY 19, 2020
Chemistry & Physics
MAY 19, 2020
Our COVID Fight Now Has a Formidable "AI"ly
This March, amid the sharp rising number of COVID-19 cases, a call to action to the artificial intelligence (AI) communi ...
MAY 22, 2020
Genetics & Genomics
MAY 22, 2020
ALK - The Skinny Gene?
Some people have to count calories and exercise regularly to be skinny while others can consume whatever they want and n ...
MAY 25, 2020
Microbiology
MAY 25, 2020
Assessing the Risk of COVID-19 Posed by Various Summer Activities
While we know a lot more about the pandemic virus SARS-CoV-2 and the illness it causes, COVID-19, there are still many u ...
MAY 26, 2020
Technology
MAY 26, 2020
An App That Detects Retinal Damage
The most common cause of blindness in working-age adults is retinal damage as a result of diabetes. To address this prob ...
MAY 29, 2020
Genetics & Genomics
MAY 29, 2020
Advances in Our Understanding of Huntington's Disease
Huntington's disease (HD) is a fatal neurodegenerative disease caused by an expanded sequence in the huntingtin gene.
Loading Comments...